IL1B — Interleukin-1 Beta
Overview
Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine that serves as a master regulator of neuroinflammation in the central nervous system. Produced primarily by microglia, astrocytes, and infiltrating immune cells, IL-1β drives a cascade of inflammatory responses that contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and other neurodegenerative conditions [1](https://doi.org/10.1016/j.neuropharm.2020.108014). The cytokine is encoded by the IL1B gene on chromosome 2q14.1 and is synthesized as an inactive propeptide (pro-IL-1β) that requires proteolytic cleavage by caspase-1 within the NLRP3 inflammasome complex to become biologically active.
Pathway Diagram
...IL1B — Interleukin-1 Beta
Overview
Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine that serves as a master regulator of neuroinflammation in the central nervous system. Produced primarily by microglia, astrocytes, and infiltrating immune cells, IL-1β drives a cascade of inflammatory responses that contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and other neurodegenerative conditions [1](https://doi.org/10.1016/j.neuropharm.2020.108014). The cytokine is encoded by the IL1B gene on chromosome 2q14.1 and is synthesized as an inactive propeptide (pro-IL-1β) that requires proteolytic cleavage by caspase-1 within the NLRP3 inflammasome complex to become biologically active.
Pathway Diagram
Mermaid diagram (expand to render)
Protein Infobox
<div class="infobox infobox-protein">
<table>
<tr><th>Protein Name</th><td>Interleukin-1 Beta (IL-1β)</td></tr>
<tr><th>Gene</th><td>[IL1B](/genes/il1b)</td></tr>
<tr><th>UniProt ID</th><td>[P01584](https://www.uniprot.org/uniprot/P01584)</td></tr>
<tr><th>Molecular Weight</th><td>~31 kDa (active form)</td></tr>
<tr><th>Protein Length</th><td>269 amino acids (active)</td></tr>
<tr><th>Protein Fold</th><td>Beta-trefoil fold</td></tr>
<tr><th>Subcellular Localization</th><td>Secreted, cytosol</td></tr>
<tr><th>Expression</th><td>Microglia, astrocytes, neurons, immune cells</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">971 edges</a></td>
</tr>
</table>
</div>
Molecular Biology and Processing
Gene Structure and Regulation
The IL1B gene spans approximately 9.5 kb and consists of 7 exons. Expression is tightly regulated at multiple levels:
- Transcriptional Control: NF-κB and AP-1 binding sites in the IL1B promoter drive transcription in response to pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and other inflammatory signals
- Post-transcriptional Regulation: mRNA stability elements and microRNA binding (e.g., miR-155) modulate IL1B mRNA half-life
- Epigenetic Control: DNA methylation and histone modifications influence IL1B expression in different cell types
Protein Processing and Maturation
IL-1β is synthesized as a 31 kDa propeptide (pro-IL-1β, amino acids 1-269) that lacks biological activity. Activation requires proteolytic cleavage:
Inflammasome Assembly: Pattern recognition receptors (e.g., NLRP3) detect cellular stress signals and assemble the inflammasome complex containing procaspase-1
Caspase-1 Activation: Autocatalysis converts procaspase-1 to active caspase-1
Pro-IL-1β Cleavage: Caspase-1 cleaves pro-IL-1β between Asp116 and Ala117, releasing the 17 kDa active fragment (amino acids 117-269)
Secretion: The active IL-1β is secreted via gasdermin D pores or alternative pathwaysReceptor Binding and Signaling
IL-1β signals through the IL-1 receptor complex:
- IL-1 Receptor Type I (IL-1R1): The signaling receptor, requiring the IL-1 receptor accessory protein (IL-1RAP) for signal transduction
- IL-1 Receptor Type II (IL-1R2): A decoy receptor that sequesters IL-1β and prevents signaling
- IL-1 Receptor Antagonist (IL-1RA): A natural antagonist that blocks IL-1R1 binding
Upon binding, the IL-1R1/IL-1RAP complex activates:
MyD88-dependent signaling: Adaptor protein MyD88 recruits IRAK kinases
NF-κB activation: TRAF6 ubiquitination leads to IKK complex activation and IκB degradation
MAPK activation: JNK, p38, and ERK pathways are also activated
Gene transcription: Pro-inflammatory genes including IL6, TNF, and itself are expressedNormal Physiological Function
CNS Homeostasis
Under normal conditions, IL-1β plays essential roles in brain function:
- Synaptic Plasticity: Low-level IL-1β signaling supports long-term potentiation (LTP) and memory formation
- Sleep Regulation: IL-1β participates in sleep-wake cycles and sleep homeostasis
- Neurogenesis: Modulates neural progenitor cell proliferation and differentiation
- Thermoregulation: Contributes to fever responses during infection
Immune Surveillance
The cytokine maintains CNS immune vigilance:
- Microglial Activation: Baseline IL-1β maintains microglial surveillance state
- Response to Injury: Rapidly upregulated following CNS injury or infection
- Host Defense: Essential for protective inflammatory responses to pathogens
Role in Neurodegenerative Diseases
Alzheimer's Disease
IL-1β is centrally implicated in AD pathogenesis through multiple mechanisms [2](https://doi.org/10.1016/j.jad.2020.12.091):
Amyloid Pathology
- Plaque Association: IL-1β colocalizes with amyloid-beta plaques in AD brain tissue
- APP Processing: IL-1β signaling increases amyloid precursor protein (APP) processing and Aβ production via NF-κB
- Aggregation Modulation: IL-1β affects Aβ aggregation kinetics and plaque formation
- NLRP3 Inflammasome: Aβ activates NLRP3, creating a feed-forward loop of IL-1β production [6](https://doi.org/10.1038/s41577-023-00787-0)
Tau Pathology [3](https://doi.org/10.1186/s40478-019-0722-4)
- Kinase Activation: IL-1β activates GSK3β and CDK5, key tau kinases
- Phosphorylation: Promotes tau phosphorylation at multiple AD-relevant sites (Ser396, Thr231, AT8)
- Tangle Formation: Facilitates tau aggregation and neurofibrillary tangle formation
- Spread Propagation: May contribute to tau pathology propagation between brain regions
Synaptic Dysfunction [9](https://doi.org/10.1038/s41593-022-01076-8)
- Synaptic Pruning: IL-1β promotes excessive microglial phagocytosis of synapses
- LTP Impairment: Chronic IL-1β exposure disrupts long-term potentiation
- Dendritic Spine Loss: Reduces dendritic spine density on hippocampal neurons
- Memory Deficits: IL-1β overexpression in hippocampus impairs spatial memory
Neuroinflammation [11](https://doi.org/10.1038/s41582-019-0268-9)
- Microglial Activation: Sustains chronic microglial activation (" microglia)
- Cytokine Cascade: Triggers production of other pro-inflammatory cytokines (IL-6, TNF-α)
- Blood-Brain Barrier: Compromises BBB integrity, allowing peripheral immune cell infiltration
Parkinson's Disease
IL-1β contributes to PD through multiple mechanisms [15](https://doi.org/10.1038/s41583-022-00552-1):
- Dopaminergic Neuron Loss: IL-1β is toxic to substantia nigra dopaminergic neurons
- Microglial Activation: Chronic activation of nigral microglia by IL-1β
- Inflammasome Activation: NLRP3 inflammasome in PD microglia produces IL-1β
- α-Synuclein Interplay: IL-1β accelerates α-synuclein aggregation and propagation
- Neuroinflammation: Elevated IL-1β in substantia nigra, CSF, and blood of PD patients
Amyotrophic Lateral Sclerosis [13](https://doi.org/10.1093/brain/awab395)
- Motor Neuron Toxicity: IL-1β directly damages upper and lower motor neurons
- Microglial Activation: Sustained neuroinflammatory response in spinal cord
- Disease Progression: IL-1β levels correlate with disease progression rate
- Therapeutic Target: IL-1R1 antagonists show promise in preclinical models
Multiple Sclerosis [14](https://doi.org/10.1038/s41582-020-0383-7)
- Demyelination: IL-1β promotes oligodendrocyte death and demyelination
- Blood-Brain Barrier Breakdown: Facilitates leukocyte infiltration into CNS
- T-cell Activation: Supports Th1 and Th17 responses
- Disease Progression: IL-1β blockade reduces disease activity in MS models
Frontotemporal Dementia
- Tau Pathology: IL-1β contributes to tau phosphorylation and aggregation
- Neuroinflammation: Similar microglial activation patterns as AD
- Behavioral Symptoms: Cytokine-induced changes in frontal cortex function
Therapeutic Targeting
IL-1 Targeting Strategies [10](https://doi.org/10.1093/brain/awab467)
Approved Biological Agents
Anakinra (Kineret): Recombinant IL-1RA; FDA-approved for rheumatoid arthritis
Canakinumab (Ilaris): Anti-IL-1β monoclonal antibody; approved for periodic fever syndromes
Rilonacept (Arcalyst): IL-1R-Fc fusion protein; traps IL-1β and IL-1αClinical Trials in Neurodegeneration
- AD Trials: Canakinumab failed in Phase 3 AD trial (CANTOS sub-study)
- PD Trials: Anakinra in early-phase PD trials (safety established, efficacy unclear)
- ALS Trials: IL-1 blockade showing mixed results in Phase 2
Experimental Approaches
- NLRP3 Inhibitors: Targeting upstream inflammasome activation [6](https://doi.org/10.1038/s41577-023-00787-0)
- Small Molecule IL-1R1 Antagonists: Blood-brain barrier penetrant compounds
- Gene Therapy: AAV-delivered IL-1RA or IL-1R1 decoy
- MicroRNA-based: miR-155 antagonists to reduce IL-1β production
Biomarker Potential
- CSF IL-1β: Elevated in AD, PD, and MS; potential diagnostic aid
- Blood IL-1β: Peripheral biomarker candidate (limited CNS specificity)
- PET Inflammation: IL-1R1 imaging for neuroinflammation visualization
Protein-Protein Interactions
Signaling Complex
- IL-1R1: Primary signaling receptor
- IL-1RAP: Accessory protein required for signaling
- MyD88: Downstream adaptor protein
- IRAK1/4: Kinase cascade members
- TRAF6: E3 ubiquitin ligase
Inflammasome Components
- NLRP3: Pattern recognition receptor forming inflammasome
- ASC: Adaptor protein linking NLRP3 to caspase-1
- Pro-caspase-1: Zymogen for caspase-1 activation
- Gasdermin D: Pore-forming protein for IL-1β secretion
Anti-inflammatory Interactors
- IL-1RA: Natural antagonist
- IL-1R2: Decoy receptor
- SIGIRR: Single Ig IL-1R-related molecule (negative regulator)
Animal Models
| Model | Description | IL-1β Relevance | Therapeutic Target |
|-------|-------------|-----------------|---------------------|
| APP/PS1 mice | AD model | Elevated IL-1β near plaques | IL-1R1 blockade |
| 5xFAD mice | AD model | Microglial IL-1β activation | NLRP3 inhibitors |
| MPTP mice | PD model | Nigral IL-1β elevation | IL-1RA |
| α-synuclein Tg | PD model | IL-1β in Lewy bodies | Anti-IL-1β |
| SOD1 Tg mice | ALS model | Spinal cord IL-1β | IL-1R1 antagonist |
| EAE mice | MS model | IL-1β drives demyelination | NLRP3 inhibition |
Research Directions
Unresolved Questions
What triggers chronic IL-1β elevation in neurodegenerative disease?
Is IL-1β cause or consequence of neurodegeneration?
Can selective CNS IL-1β targeting avoid peripheral immunosuppression?
What determines patient response to IL-1 blockade?Emerging Research
- Single-cell analysis: IL-1β production by specific microglial subsets
- Inflammasome imaging: PET ligands for NLRP3 visualization
- Personalized medicine: IL1B genetic variants affecting treatment response
- Combination therapy: IL-1 targeting with disease-modifying agents
Cross-Links
- [NLRP3 Protein](/proteins/nlrp3-protein) — Inflammasome component
- [Caspase-1 Protein](/proteins/caspase1) — IL-1β activating enzyme
- [TNF-α Protein](/proteins/tnf-alpha) — Related inflammatory cytokine
- [IL-6 Protein](/proteins/il6-protein) — Pro-inflammatory cytokine
- [IL1B Gene](/genes/il1b) — IL-1 beta gene
- [IL1R1 Gene](/genes/il1r1) — IL-1 receptor type I
- [IL1RA Gene](/genes/il1ra) — IL-1 receptor antagonist
- [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome) — IL-1β activation pathway
- [Neuroinflammation in AD](/mechanisms/neuroinflammation-ad) — AD-specific inflammation
- [Microglial Activation](/mechanisms/microglial-activation) — CNS immune cells
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Primary IL-1β target
- [Parkinson's Disease](/diseases/parkinsons-disease) — IL-1β in PD
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — IL-1β in ALS
- [Multiple Sclerosis](/diseases/multiple-sclerosis) — IL-1β in MS
References
[Müller et al., Interleukin-1 in the pathogenesis of Parkinson's disease (2020)](https://doi.org/10.1016/j.neuropharm.2020.108014)
[Song et al., NLRP3 inflammasome and Alzheimer's disease (2021)](https://doi.org/10.1016/j.jad.2020.12.091)
[Li et al., IL-1β and tau pathology (2019)](https://doi.org/10.1186/s40478-019-0722-4)
[Hennessy et al., Microglial IL-1β in neurodegeneration (2022)](https://doi.org/10.1007/s00401-022-02407-w)
[Brough et al., IL-1 receptor antagonist for neuroprotection (2021)](https://doi.org/10.1016/j.pharmthera.2021.107852)
[Manneras et al., NLRP3 inflammasome in neuroinflammation (2023)](https://doi.org/10.1038/s41577-023-00787-0)
[Rothman et al., IL-1β signaling in the brain (2020)](https://doi.org/10.1038/s41583-020-00356-9)
[Patel et al., IL-1β and amyloid-beta crosstalk (2021)](https://doi.org/10.1186/s12974-021-02132-1)
[Cai et al., IL-1β and synaptic dysfunction in AD (2022)](https://doi.org/10.1038/s41593-022-01076-8)
[Green et al., Targeting IL-1β in neurodegenerative disease (2022)](https://doi.org/10.1093/brain/awab467)
[Khandelwal et al., Neuroinflammation in neurodegenerative disease (2019)](https://doi.org/10.1038/s41582-019-0268-9)
[Campisi et al., Aging, inflammaging, and neurodegeneration (2021)](https://doi.org/10.1038/s41583-021-00456-4)
[Lee et al., IL-1β in amyotrophic lateral sclerosis (2021)](https://doi.org/10.1093/brain/awab395)
[Matsumoto et al., IL-1β in multiple sclerosis pathogenesis (2020)](https://doi.org/10.1038/s41582-020-0383-7)
[Poewe et al., Parkinson's disease neuroinflammation (2022)](https://doi.org/10.1038/s41583-022-00552-1)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: NLRP3, CASP1, IL1B, PYCARD
Pathway Diagram
The following diagram shows the key molecular relationships involving IL1B — Interleukin-1 Beta discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)